Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Key Technical Features Dual-Action Kinetics: Simultaneously activates GLP-1 and Amylin receptor pathways for comprehensive cellular energy tracking
Request a Certificate of Analysis, ask about a category, or start a bulk / OEM inquiry we reply within one business day.
Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results
Is it safe in animals
US$ 21.31
US$ 23.74
US$ 25.44
US$ 23.96